Compare ResMed Inc. (RMD) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Williams Companies Inc — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Williams Companies Inc trades at $72.67 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 2.8× ResMed Inc.'s market cap, and Williams Companies Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Williams Companies Inc for 58 Days on average.
| RMD | WMB | |
|---|---|---|
Market Cap | $31.89B | $88.48B |
Volume | 618,314 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $275.96 | $79.40 |
52-Week Low | $182.82 | $56.51 |
Typical Hold Time | 51 Days | 58 Days |
Enterprise Value | $31.24B | $119.11B |
Dividend Yield | 1.16% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
WMB trades at $72.34, up 1.23% with a bullish technical signal. The company shows strong profitability with 25.18% net income margin and 24.02% ROE, though valuation ratios appear elevated with P/E of 28.82. Recent earnings show mixed results with Q1 2026 beat but Q4 2025 and Q2 2026 misses. Natural gas demand growth from AI data centers provides strategic positioning for future revenue growth.
WMB offers attractive dividend yield with 79% analyst buy ratings and $87.27 consensus target, suggesting 21% upside. Key risks include energy market volatility and high debt levels at $24.74 billion long-term debt. The stock presents opportunity for income investors seeking exposure to resilient midstream energy infrastructure with fee-based revenue model.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
